PCOS Officially Renamed to PMOS After 14-Year Global Effort to Improve Diagnosis and Awareness

PCOS Rebranded as PMOS: A 14-Year Effort to Correct a Misleading Name

Polycystic ovary syndrome (PCOS), a hormonal disorder affecting one in eight women worldwide, has been officially renamed to polyendocrine metabolic ovarian syndrome (PMOS). The change, announced on Tuesday at the European Congress of Endocrinology and published in the leading medical journal The Lancet, seeks to address decades of confusion and misdiagnosis surrounding the condition.

The new name, PMOS, reflects the condition’s complex hormonal and metabolic dysfunctions rather than its outdated association with ovarian cysts. Specialists involved in the renaming process criticized the term "PCOS" as inaccurate, noting that misunderstandings about its features led to delayed diagnoses, inadequate care, and hindered research progress.

"What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated."

Why the Name Change Matters

The new name emphasizes three key areas of dysfunction:

• Endocrine: Hormonal imbalances, including elevated androgen levels like testosterone.
• Metabolic: Increased risk of type 2 diabetes, hypertension, and cardiovascular disease.
• Ovarian: Disrupted ovulation and menstrual irregularities.

The renaming effort was the result of a 14-year global collaboration, involving input from over 50 organizations and 14,000 individuals with the condition. The new name will be officially adopted in the 2028 update to international treatment guidelines for the disorder.

"While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition."

Understanding PMOS: Symptoms and Health Risks

PMOS (formerly PCOS) is characterized by hormonal imbalances that disrupt ovulation, leading to unpredictable and often painful menstrual cycles. While the term "polycystic" suggests the presence of ovarian cysts, the condition does not typically involve true cysts. Instead, hormonal fluctuations prevent follicles from releasing eggs, creating what appears as cysts on ultrasound.

Key symptoms and health risks associated with PMOS include:

• Reproductive issues: Irregular ovulation, fertility problems, and increased risk of endometrial cancer due to prolonged estrogen exposure.
• Metabolic complications: Higher likelihood of developing type 2 diabetes, hypertension, and cardiovascular disease.
• Mental health impacts: Increased risk of depression and anxiety.
• Physical symptoms: Severe acne, excess hair growth (hirsutism), and sleep disturbances such as sleep apnea.

Unlike some conditions, PMOS lacks a simple diagnostic test and currently has no known cure. However, symptoms can be managed through hormone therapies and lifestyle modifications, particularly when patients receive an accurate and timely diagnosis.

A Step Toward Better Recognition and Care

The renaming of PCOS to PMOS marks a significant milestone in improving awareness, reducing misdiagnosis, and advancing research for a condition that impacts millions of women globally. By shifting the focus from ovarian cysts to the broader hormonal and metabolic dysfunctions, the new name aims to foster better understanding and more effective treatment strategies.